Outset Medical (NSDQ:OM) announced that it appointed Edwards Lifesciences executive Katie Szyman to its board of directors.
Szyman currently serves as corporate VP & GM of critical care at Edwards, having spent more than 30 years in leadership roles in the medtech space, according to a news release. Much of her experience came in 23 years at medtech giant Medtronic.
She held finance roles before becoming CFO of Medtronic’s coronary stent business, then working with mergers and acquisitions before moving into general management work. Her final role at Medtronic was president of its diabetes business.
“Katie’s impressive track record of ushering medical device companies through market expansion and high growth is ideally suited to Outset,” Outset Medical CEO Leslie Trigg said in the release. “Her commercial growth acumen both in the critical care and consumer diabetes space reflects our focus on transforming the dialysis experience for patients and providers in both the acute and home setting.”
At Edwards, Szyman has grown the critical care business by nearly 50% to $800 million over just six years, having produced similar success at Medtronic, where she grew the global diabetes business by more than 40% to $1.5 billion over five years heading up that division.
Szyman also serves on the board of directors at Inari Medical and the American Heart Association of Orange County. She is also on the board of governors at Opus College of Business at the University of St. Thomas.
“I’ve spent most of my career focused on innovations around patient care, and I’ve witnessed firsthand the impact medical technology can have on people’s lives,” Szyman said. “Outset is not only leading the charge when it comes to reimagining dialysis for both patients and providers but also catalyzing change in the entire dialysis care delivery model. The company’s rapid growth and aspirational objectives are driving a shift in the market, and my goal is to help accelerate that.”